Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 1Rectal Neoplasms 1Liver Neoplasms 1Hematologic Neoplasms 1Esophageal Neoplasms 1Colonic Neoplasms 1Brain Neoplasms 1

Interventions

Oxaliplatin 14Cetuximab 11Leucovorin 9Fluorouracil 9Magnetic Resonance Spectroscopy 8Nivolumab 7pembrolizumab 6Capecitabine 6encorafenib 5Irinotecan 5Bevacizumab 5dehydroftorafur 4Specimen Handling 4adagrasib 3Immunoglobulin G 3Disulfides 3Biopsy 3selpercatinib 2durvalumab 2cemiplimab 2X-Rays 2Watchful Waiting 2Standard of Care 2Radiotherapy 2Panitumumab 2Observation 2Ipilimumab 2Injections 2Gemcitabine 2Folfox protocol 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Colonic Neoplasms × ropidoxuridine × Clear all
NCT02381561 2026-04-13

Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy

National Cancer Institute (NCI)

Phase 1 Active not recruiting
19 enrolled
Gastrointestinal

Colonic Neoplasms, Esophageal Neoplasms, Liver Neoplasms, Rectal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡